wild week continu new
access agreement nh england give
patient access licens cf drug
vertex gain new access ukupd agreement provid
revenu vertex announc today reach new access agreement
nh england current licens cf medicin specif agreement give new
access orkambi age year symkevi year expand access
kalydeco age year mutat age month singl gate
mutat agreement specif includ access trikafta expect
approv nh would act quickli vertex cover therapi view
reimburs uk provid meaning upsid vertex long-term revenu
dcf valuat stock today announc remain support
outperform thesi basi revis tp
spoke compani regard agreement nh notabl
includ access trikafta assum approv uk reimburs would
follow vertex would give specif price per patient assum greater
low number nh england propos last year year product
per year approxim per patient lower price germani
european territori compani give england best price wwreflect
larg cf popul region compani readi launch within next day
could see addit upward revis guidanc expect consensu number
also increas follow announc
focu remain launch trikafta us like approv ou non cf
pipelin updat also note reimburs franc still remain believ
deal could help pressur franc formal agreement orkambi current
provid name patient basi vertex recogn revenu formal
agreement place beyond cf expect updat program
potenti updat potenti decemb
model changes/ risk increas ep base today
agreement risk clinic development commerci regulatori
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset vx-
gene-edit system
grey sky scenario model less credit trikafta due
lower expect commerci perform regulatori delay
 close
uk reimburs underappreci consensu expect base today
announc increas probabl success po uk cf portfolio sale
orkambi symkevi also increas po trikafta
assum drug approv uk uk assum
price per year across entir portfolio drug higher
previous propos per year nh estim uk repres
discount german net price
overal deal highli posit vertex given larg address popul uk
recal vertex recent reach deal scotland uk largest
concentr cf patient world approxim world
popul thu repres signific revenu opportun continu believ
upsid uk reimburs well reflect consensu estim given new
agreement expect consensu forecast give credit uk opportun
upward revis revenu valuat
non cf pipelin updat also announc today preclin data set
voluntarili invalid ind unaffect program continu unchang
compani announc today one six preclin studi use file ind
focal segment glomerular sclerosi fsg show discrep
made data set unreli vertex notifi fda find state
program continu unchang remain five data set re-verifi found
reliabl data posit phase vertex plan initi phase proof-of-concept
clinic trial bottom line comfort vertex hand situat
transpar fda note respons scientist longer compani
model chang given today new agreement uk increas estim
uk increas probabl success po uk cf portfolio sale
orkambi symkevi increas po trikafta
assum trikafta approv uk result chang
forecast revenu revenu
non-gaap ep non-gaap ep
vertex residu cf opportun ex revenu loss incom cs dilut cs charl martineau univers toronto octob
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known
expect product launch patent expir competit threat current
commerci portfolio pipelin beyond forecast period appli termin
growth rate termin cash flow believ vertex continu invest
 bd success replac revenu faster rate eros
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv vertex investig product
commerci sale
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
